SIRs and EARs of tAML by age (years) after initial chemotherapy treatment of selected first primary malignancies in adulthood, 9 SEER registries, 1975-2008.P-values were derived from Poisson regression models adjusted for year of first primary malignancy diagnosis, receipt of initial radiotherapy, sex (for lung and bronchus, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma), stage (for lung and bronchus, female breast, and ovary), and latency (1.0-4.9, 5.0-9.9, 10+ years; for lung and bronchus: 1-4.9, 5+ years). CI, confidence interval; EAR, excess absolute risk; P_hom, p for homogeneity; tAML, therapy-related acute myeloid leukemia; SIR, standardized incidence ratio; SEER, Surveillance, Epidemiology and End Results.